Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Reliq Health Technologies Inc V.RHT.H

Alternate Symbol(s):  RQHTF

Reliq Health Technologies Inc. is a global healthcare technology company that specializes in developing virtual care solutions for the healthcare market. The Company’s iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent hospital readmissions and ER visits. The iUGO Care platform integrates wearables, sensors, voice technology and mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators. The iUGO Care platform provides services, such as remote patient monitoring, chronic care management, principal care management, behavioral health integration, telemedicine, transitional care management, wound care, and others.


TSXV:RHT.H - Post by User

Post by theinvestor22on Dec 01, 2022 11:05am
154 Views
Post# 35143031

Device revenue is a tad higher that reported

Device revenue is a tad higher that reportedOne small point on revenue is that not all of the device price makes it into the revenue line.  On contracts exceeding 12 months, some of the device price goes unreported in the revenue line and shows up as interest in subsequent quarters.  (See note 2.ii. in the latest financials.)  fQ4 had about $77k recognized as interest income which was really just deferred recognition of device sales.  Further, at that time, an additional $230k was deferred until later, which means that f2022 really had something in the order of $330k higher device sales than reported.

In fQ1, about $81k was recognized as interest from previous period sales.  All of this, as mentioned above really is revenue, in this case mostly from f2022 sales.  Like I said, this isn't a big point, but perhaps >$100k of Q1 device sales didn't get reported in the revenue line for fQ1.
<< Previous
Bullboard Posts
Next >>